Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells

{ 'indexed': { 'date-parts': [[2022, 12, 27]], 'date-time': '2022-12-27T12:53:44Z', 'timestamp': 1672145624652}, 'reference-count': 39, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2022, 9, 16]], 'date-time': '2022-09-16T00:00:00Z', 'timestamp': 1663286400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 9, 16]], 'date-time': '2022-09-16T00:00:00Z', 'timestamp': 1663286400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'DOI': '10.13039/100009619', 'name': 'the Japan Agency for Medical Research and Development', 'doi-asserted-by': 'crossref', 'award': ['JP20he0822004']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Many therapeutic antibodies (Abs) and mRNA vaccines, ' 'both targeting SARS-CoV-2 spike protein (S-protein), have been developed and approved in ' 'order to combat the ongoing COVID-19 pandemic. In consideration of these developments, a ' 'common concern has been the potential for Ab-dependent enhancement (ADE) of infection caused ' 'by inoculated or induced Abs. Although the preventive and therapeutic effects of these Abs ' 'are obvious, little attention has been paid to the influence of the remaining and dwindling ' 'anti-S-protein Abs in vivo. Here, we demonstrate that certain monoclonal Abs (mAbs) approved ' 'as therapeutic neutralizing anti-S-protein mAbs for human usage have the potential to cause ' 'ADE in a narrow range of Ab concentrations. Although sera collected from mRNA-vaccinated ' 'individuals exhibited neutralizing activity, some sera gradually exhibited dominance of ADE ' 'activity in a time-dependent manner. None of the sera examined exhibited neutralizing ' 'activity against infection with the Omicron strain. Rather, some ADE of Omicron infection was ' 'observed in some sera. These results suggest the possible emergence of adverse effects caused ' 'by these Abs in addition to the therapeutic or preventive effect.</jats:p>', 'DOI': '10.1038/s41598-022-19993-w', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 16]], 'date-time': '2022-09-16T16:04:09Z', 'timestamp': 1663344249000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic ' 'antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells', 'prefix': '10.1038', 'volume': '12', 'author': [ {'given': 'Jun', 'family': 'Shimizu', 'sequence': 'first', 'affiliation': []}, {'given': 'Tadahiro', 'family': 'Sasaki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ritsuko', 'family': 'Koketsu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ryo', 'family': 'Morita', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yuka', 'family': 'Yoshimura', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ami', 'family': 'Murakami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yua', 'family': 'Saito', 'sequence': 'additional', 'affiliation': []}, {'given': 'Toshie', 'family': 'Kusunoki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yoshihiro', 'family': 'Samune', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emi E.', 'family': 'Nakayama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kazuo', 'family': 'Miyazaki', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tatsuo', 'family': 'Shioda', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 9, 16]]}, 'reference': [ { 'key': '19993_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1010', 'DOI': '10.1126/science.abd0827', 'volume': '369', 'author': 'J Hansen', 'year': '2020', 'unstructured': 'Hansen, J. et al. Studies in humanized mice and convalescent humans ' 'yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).', 'journal-title': 'Science'}, { 'key': '19993_CR2', 'doi-asserted-by': 'publisher', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'volume': '384', 'author': 'DM Weinreich', 'year': '2021', 'unstructured': 'Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in ' 'outpatients with covid-19. N. Engl. J. Med. 384, 238–251 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR3', 'doi-asserted-by': 'publisher', 'first-page': '2047', 'DOI': '10.1007/s40265-021-01620-z', 'volume': '81', 'author': 'ED Deeks', 'year': '2021', 'unstructured': 'Deeks, E. D. Casirivimab/Imdevimab: First approval. Drugs 81, 2047–2055 ' '(2021).', 'journal-title': 'Drugs'}, { 'key': '19993_CR4', 'doi-asserted-by': 'publisher', 'first-page': '643', 'DOI': '10.1056/NEJMra2035343', 'volume': '384', 'author': 'MC Castells', 'year': '2021', 'unstructured': 'Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 ' 'vaccines. N. Engl. J. Med. 384, 643–649 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR5', 'doi-asserted-by': 'publisher', 'first-page': '2187', 'DOI': '10.1056/NEJMoa2101544', 'volume': '384', 'author': 'J Sadoff', 'year': '2021', 'unstructured': 'Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S Vaccine ' 'against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR6', 'doi-asserted-by': 'publisher', 'first-page': '403', 'DOI': '10.1056/NEJMoa2035389', 'volume': '384', 'author': 'LR Baden', 'year': '2021', 'unstructured': 'Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 ' 'vaccine. N. Engl. J. Med. 384, 403–416 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR7', 'doi-asserted-by': 'publisher', 'first-page': '671', 'DOI': '10.1016/S0140-6736(21)00234-8', 'volume': '397', 'author': 'DY Logunov', 'year': '2021', 'unstructured': 'Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 ' 'vector-based heterologous prime-boost COVID-19 vaccine: An interim ' 'analysis of a randomised controlled phase 3 trial in Russia. The Lancet ' '397, 671–681 (2021).', 'journal-title': 'The Lancet'}, { 'key': '19993_CR8', 'doi-asserted-by': 'publisher', 'first-page': '2', 'DOI': '10.1038/s41541-016-0003-3', 'volume': '2', 'author': 'M Xu', 'year': '2017', 'unstructured': 'Xu, M. et al. A potent neutralizing antibody with therapeutic potential ' 'against all four serotypes of dengue virus. NPJ Vaccines 2, 2 (2017).', 'journal-title': 'NPJ Vaccines'}, { 'key': '19993_CR9', 'doi-asserted-by': 'publisher', 'first-page': '505', 'DOI': '10.1016/j.vaccine.2008.10.087', 'volume': '27', 'author': 'W Huisman', 'year': '2009', 'unstructured': 'Huisman, W., Martina, B. E., Rimmelzwaan, G. F., Gruters, R. A. & ' 'Osterhaus, A. D. Vaccine-induced enhancement of viral infections. ' 'Vaccine 27, 505–512 (2009).', 'journal-title': 'Vaccine'}, { 'key': '19993_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1195', 'DOI': '10.1056/NEJMoa1506223', 'volume': '373', 'author': 'SR Hadinegoro', 'year': '2015', 'unstructured': 'Hadinegoro, S. R. et al. Efficacy and long-term safety of a dengue ' 'vaccine in regions of endemic disease. N. Engl. J. Med. 373, 1195–1206 ' '(2015).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR11', 'doi-asserted-by': 'publisher', 'first-page': '1185', 'DOI': '10.1038/s41564-020-00789-5', 'volume': '5', 'author': 'WS Lee', 'year': '2020', 'unstructured': 'Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. ' 'Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. ' 'Nat. Microbiol. 5, 1185–1191 (2020).', 'journal-title': 'Nat. Microbiol.'}, { 'key': '19993_CR12', 'doi-asserted-by': 'publisher', 'first-page': '4203', 'DOI': '10.1016/j.cell.2021.06.021', 'volume': '184', 'author': 'D Li', 'year': '2021', 'unstructured': 'Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 ' 'infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219 ' '(2021).', 'journal-title': 'Cell'}, { 'key': '19993_CR13', 'doi-asserted-by': 'publisher', 'first-page': '5752', 'DOI': '10.1038/s41467-020-19568-1', 'volume': '11', 'author': 'S Wang', 'year': '2020', 'unstructured': 'Wang, S. et al. Characterization of neutralizing antibody with ' 'prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus ' 'monkeys. Nat. Commun. 11, 5752 (2020).', 'journal-title': 'Nat. Commun.'}, { 'key': '19993_CR14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.celrep.2021.108699', 'volume': '34', 'author': 'Y Zhou', 'year': '2021', 'unstructured': 'Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 ' 'antibodies from a convalescent donor associates with distinct epitopes ' 'on the RBD. Cell Rep. 34, 108699 (2021).', 'journal-title': 'Cell Rep.'}, { 'key': '19993_CR15', 'doi-asserted-by': 'publisher', 'first-page': '867', 'DOI': '10.1007/s00408-020-00408-4', 'volume': '198', 'author': 'F Scialo', 'year': '2020', 'unstructured': 'Scialo, F. et al. ACE2: The major cell entry receptor for SARS-CoV-2. ' 'Lung 198, 867–877 (2020).', 'journal-title': 'Lung'}, { 'key': '19993_CR16', 'doi-asserted-by': 'publisher', 'first-page': '281', 'DOI': '10.1016/j.cell.2020.02.058', 'volume': '181', 'author': 'AC Walls', 'year': '2020', 'unstructured': 'Walls, A. C. et al. Structure, function, and antigenicity of the ' 'SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).', 'journal-title': 'Cell'}, { 'key': '19993_CR17', 'doi-asserted-by': 'publisher', 'first-page': '905', 'DOI': '10.1016/j.cell.2020.04.004', 'volume': '181', 'author': 'V Monteil', 'year': '2020', 'unstructured': 'Monteil, V. et al. Inhibition of SARS-CoV-2 infections in engineered ' 'human tissues using clinical-grade soluble human ACE2. Cell 181, 905–913 ' '(2020).', 'journal-title': 'Cell'}, { 'key': '19993_CR18', 'doi-asserted-by': 'publisher', 'first-page': '288', 'DOI': '10.1038/s41467-020-20602-5', 'volume': '12', 'author': 'C Kim', 'year': '2021', 'unstructured': 'Kim, C. et al. A therapeutic neutralizing antibody targeting receptor ' 'binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021).', 'journal-title': 'Nat. Commun.'}, { 'key': '19993_CR19', 'doi-asserted-by': 'publisher', 'first-page': '12448', 'DOI': '10.1038/s41598-021-91746-7', 'volume': '11', 'author': 'D Mannar', 'year': '2021', 'unstructured': 'Mannar, D., Leopold, K. & Subramaniam, S. Glycan reactive anti-HIV-1 ' 'antibodies bind the SARS-CoV-2 spike protein but do not block viral ' 'entry. Sci. Rep. 11, 12448 (2021).', 'journal-title': 'Sci. Rep.'}, { 'key': '19993_CR20', 'doi-asserted-by': 'publisher', 'first-page': '3949', 'DOI': '10.1016/j.cell.2021.06.002', 'volume': '184', 'author': 'R Copin', 'year': '2021', 'unstructured': 'Copin, R. et al. The monoclonal antibody combination REGEN-COV protects ' 'against SARS-CoV-2 mutational escape in preclinical and human studies. ' 'Cell 184, 3949–3961 (2021).', 'journal-title': 'Cell'}, { 'key': '19993_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1014', 'DOI': '10.1126/science.abd0831', 'volume': '369', 'author': 'A Baum', 'year': '2020', 'unstructured': 'Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents ' 'rapid mutational escape seen with individual antibodies. Science 369, ' '1014–1018 (2020).', 'journal-title': 'Science'}, { 'key': '19993_CR22', 'unstructured': 'Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) ' 'of Regen-Cov (Casirivimab and Imdevimab) ' 'https://www.fda.gov/media/145611/download.) (2021).'}, { 'key': '19993_CR23', 'doi-asserted-by': 'publisher', 'first-page': 'e0198721', 'DOI': '10.1128/mBio.01987-21', 'volume': '12', 'author': 'T Maemura', 'year': '2021', 'unstructured': 'Maemura, T. et al. Antibody-dependent enhancement of SARS-CoV-2 ' 'infection is mediated By the IgG receptors FcgammaRIIA and FcgammaRIIIA ' 'but does not contribute to aberrant cytokine production by macrophages. ' 'mBio 12, e0198721 (2021).', 'journal-title': 'mBio'}, { 'key': '19993_CR24', 'doi-asserted-by': 'publisher', 'first-page': '103720', 'DOI': '10.1016/j.isci.2021.103720', 'volume': '25', 'author': 'Z Wang', 'year': '2022', 'unstructured': 'Wang, Z. et al. ACE2 can act as the secondary receptor in the ' 'FcγR-dependent ADE of SARS-CoV-2 infection. iScience 25, 103720 (2022).', 'journal-title': 'iScience'}, { 'key': '19993_CR25', 'doi-asserted-by': 'publisher', 'first-page': '23713', 'DOI': '10.1038/s41598-021-03273-0', 'volume': '11', 'author': 'J Shimizu', 'year': '2021', 'unstructured': 'Shimizu, J. et al. The potential of COVID-19 patients’ sera to cause ' 'antibody-dependent enhancement of infection and IL-6 production. Sci. ' 'Rep. 11, 23713 (2021).', 'journal-title': 'Sci. Rep.'}, { 'key': '19993_CR26', 'first-page': '1123', 'volume': '35', 'author': 'AL Cathcart', 'year': '2021', 'unstructured': 'Cathcart, A. L. et al. The dual function monoclonal antibodies VIR-7831 ' 'and VIR-7832 demonstrate potent in vitro and in vivo activity against ' 'SARS-CoV-2. bioRxiv 35, 1123 (2021).', 'journal-title': 'bioRxiv'}, { 'key': '19993_CR27', 'doi-asserted-by': 'publisher', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'volume': '385', 'author': 'A Gupta', 'year': '2021', 'unstructured': 'Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 ' 'neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950 ' '(2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR28', 'doi-asserted-by': 'publisher', 'first-page': '679', 'DOI': '10.1038/s41586-022-04411-y', 'volume': '603', 'author': 'R Viana', 'year': '2022', 'unstructured': 'Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron ' 'variant in southern Africa. Nature 603, 679–686 (2022).', 'journal-title': 'Nature'}, { 'key': '19993_CR29', 'doi-asserted-by': 'publisher', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'volume': '386', 'author': 'E Takashita', 'year': '2022', 'unstructured': 'Takashita, E. et al. Efficacy of antibodies and antiviral drugs against ' 'covid-19 omicron variant. N. Engl. J. Med. 386, 995–998 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR30', 'doi-asserted-by': 'publisher', 'first-page': '3452', 'DOI': '10.1016/j.cell.2021.05.032', 'volume': '184', 'author': 'Y Liu', 'year': '2021', 'unstructured': 'Liu, Y. et al. An infectivity-enhancing site on the SARS-CoV-2 spike ' 'protein targeted by antibodies. Cell 184, 3452–3466 (2021).', 'journal-title': 'Cell'}, { 'key': '19993_CR31', 'doi-asserted-by': 'publisher', 'first-page': '2259', 'DOI': '10.1056/NEJMc2103916', 'volume': '384', 'author': 'N Doria-Rose', 'year': '2021', 'unstructured': 'Doria-Rose, N. et al. Antibody persistence through 6 months after the ' 'second dose of mRNA-1273 vaccine for Covid-19. N. Engl. J. Med. 384, ' '2259–2261 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '19993_CR32', 'unstructured': 'Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity ' '(https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html).) ' '(2021).'}, { 'key': '19993_CR33', 'doi-asserted-by': 'publisher', 'author': 'S Qin', 'year': '2021', 'unstructured': 'Qin, S. et al. Genome characterization and potential risk assessment of ' 'the novel SARS-CoV-2 variant omicron (B.1.1.529). Zoonoses ' 'https://doi.org/10.15212/ZOONOSES-2021-0024 (2021).', 'journal-title': 'Zoonoses', 'DOI': '10.15212/ZOONOSES-2021-0024'}, { 'key': '19993_CR34', 'doi-asserted-by': 'publisher', 'first-page': '654', 'DOI': '10.1038/s41586-021-04387-1', 'volume': '602', 'author': 'S Cele', 'year': '2021', 'unstructured': 'Cele, S. et al. Omicron extensively but incompletely escapes Pfizer ' 'BNT162b2 neutralization. Nature 602, 654–656 (2021).', 'journal-title': 'Nature'}, { 'key': '19993_CR35', 'doi-asserted-by': 'publisher', 'first-page': '706', 'DOI': '10.1038/s41586-022-04474-x', 'volume': '603', 'author': 'B Meng', 'year': '2022', 'unstructured': 'Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts ' 'tropism and fusogenicity. Nature 603, 706–714 (2022).', 'journal-title': 'Nature'}, { 'key': '19993_CR36', 'doi-asserted-by': 'publisher', 'first-page': '852', 'DOI': '10.1038/s41467-022-28544-w', 'volume': '13', 'author': 'J Zou', 'year': '2022', 'unstructured': 'Zou, J. et al. Neutralization against Omicron SARS-CoV-2 from previous ' 'non-Omicron infection. Nat. Commun. 13, 852 (2022).', 'journal-title': 'Nat. Commun.'}, { 'key': '19993_CR37', 'doi-asserted-by': 'publisher', 'DOI': '10.1172/jci.insight.92428', 'volume': '2', 'author': 'YW Kam', 'year': '2017', 'unstructured': 'Kam, Y. W. et al. Cross-reactive dengue human monoclonal antibody ' 'prevents severe pathologies and death from Zika virus infections. JCI ' 'Insight 2, e92428 (2017).', 'journal-title': 'JCI Insight'}, { 'key': '19993_CR38', 'doi-asserted-by': 'publisher', 'first-page': '1400', 'DOI': '10.1016/j.humimm.2013.05.017', 'volume': '74', 'author': 'M Haruta', 'year': '2013', 'unstructured': 'Haruta, M. et al. Generation of a large number of functional dendritic ' 'cells from human monocytes expanded by forced expression of cMYC plus ' 'BMI1. Hum. Immunol. 74, 1400–1408 (2013).', 'journal-title': 'Hum. Immunol.'}, { 'key': '19993_CR39', 'doi-asserted-by': 'publisher', 'first-page': '504', 'DOI': '10.1038/gt.2012.59', 'volume': '20', 'author': 'M Haruta', 'year': '2013', 'unstructured': 'Haruta, M. et al. TAP-deficient human iPS cell-derived myeloid cell ' 'lines as unlimited cell source for dendritic cell-like ' 'antigen-presenting cells. Gene Ther. 20, 504–513 (2013).', 'journal-title': 'Gene Ther.'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-19993-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-19993-w', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-19993-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 9, 16]], 'date-time': '2022-09-16T16:17:13Z', 'timestamp': 1663345033000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-19993-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 9, 16]]}, 'references-count': 39, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2022, 12]]}}, 'alternative-id': ['19993'], 'URL': 'http://dx.doi.org/10.1038/s41598-022-19993-w', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2022, 9, 16]]}, 'assertion': [ { 'value': '3 May 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 September 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '16 September 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '15612'}